

# Betty K Hamilton

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7780531/publications.pdf>

Version: 2024-02-01

90  
papers

1,430  
citations

377584

21  
h-index

445137

33  
g-index

91  
all docs

91  
docs citations

91  
times ranked

2310  
citing authors

#	ARTICLE	IF	CITATIONS
1	The mutational landscape in chronic myelomonocytic leukemia and its impact on allogeneic hematopoietic cell transplantation outcomes: a Center for Blood and Marrow Transplantation Research (CIBMTR) analysis. <i>Haematologica</i> , 2023, 108, 150-160.	1.7	10
2	Chronic Graft-versus-Host Disease, Nonrelapse Mortality, and Disease Relapse in Older versus Younger Adults Undergoing Matched Allogeneic Peripheral Blood Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Analysis. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 34-42.	0.6	13
3	Comparison of Quality of Life and Outcomes between Haploidentical and Matched Related/Unrelated Donor Allogeneic Hematopoietic Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 217.e1-217.e6.	0.6	4
4	Community health status and long-term outcomes in 1-year survivors of autologous and allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2022, 57, 671-673.	1.3	2
5	Sex-Specific Cardiovascular Risks of Cancer and Its Therapies. <i>Circulation Research</i> , 2022, 130, 632-651.	2.0	29
6	Noninfectious Pulmonary Toxicity after Allogeneic Hematopoietic Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 310-320.	0.6	11
7	Evaluation of pre-transplant risk assessments in allogeneic hematopoietic cell transplant. <i>Bone Marrow Transplantation</i> , 2022, 57, 1031-1033.	1.3	1
8	Male-specific late effects in adult hematopoietic cell transplantation recipients: a systematic review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2022, 57, 1150-1163.	1.3	2
9	Are We Making PROGRESS in Preventing Graft-versus-Host Disease and Improving Clinical Outcomes? Impact of BMT CTN 1301 Study Results on Clinical Practice. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 419-425.	0.6	2
10	Decitabine- and 5-azacytidine resistance emerges from adaptive responses of the pyrimidine metabolism network. <i>Leukemia</i> , 2021, 35, 1023-1036.	3.3	62
11	Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myeloid Leukemia: An Evidence-Based Review from the American Society of Transplantation and Cellular Therapy. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 6-20.	0.6	45
12	Systematic reviews in hematopoietic cell transplantation and cellular therapy: considerations and guidance from the American Society for Transplantation and Cellular Therapy, European Society for Blood and Marrow Transplantation, and the Center for International Blood and Marrow Transplant Research late effects and quality of life working committee. <i>Bone Marrow Transplantation</i> , 2021, 56, 786-797.	1.3	5
13	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2020 Etiology and Prevention Working Group Report. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 452-466.	0.6	24
14	Systematic Reviews in Hematopoietic Cell Transplantation and Cellular Therapy: Considerations and Guidance from the American Society for Transplantation and Cellular Therapy, European Society for Blood and Marrow Transplantation, and Center for International Blood and Marrow Transplant Research Late Effects and Quality of Life Working Committee. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 380-388.	0.6	4
15	Post-Transplantation Cyclophosphamide. <i>JACC: CardioOncology</i> , 2021, 3, 260-262.	1.7	1
16	Influence of Killer Immunoglobulin-Like Receptors and Somatic Mutations on Transplant Outcomes in Acute Myeloid Leukemia. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 917.e1-917.e9.	0.6	3
17	Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2021: Looking Forward as the Network Celebrates its 20th Year. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 885-907.	0.6	12
18	Personalized Prediction Model to Risk Stratify Patients With Myelodysplastic Syndromes. <i>Journal of Clinical Oncology</i> , 2021, 39, 3737-3746.	0.8	90

#	ARTICLE	IF	CITATIONS
19	Initial therapy for chronic graft-versus-host disease: analysis of practice variation and failure-free survival. <i>Blood Advances</i> , 2021, 5, 4549-4559.	2.5	8
20	Nonrelapse mortality among patients diagnosed with chronic GVHD: an updated analysis from the Chronic GVHD Consortium. <i>Blood Advances</i> , 2021, 5, 4278-4284.	2.5	36
21	Outcomes and factors impacting use of axicabtagene ciloleucel in patients with relapsed or refractory large B-cell lymphoma: results from an intention-to-treat analysis. <i>Leukemia and Lymphoma</i> , 2021, 62, 1344-1352.	0.6	7
22	Day 100 risk assessment tool predicts overall survival in allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, , .	1.3	0
23	The similarity of class II HLA genotypes defines patterns of autoreactivity in idiopathic bone marrow failure disorders. <i>Blood</i> , 2021, 138, 2781-2798.	0.6	27
24	Randomized Trial of Tacrolimus and Methotrexate Versus Tacrolimus, Reduced Dose Methotrexate, and Mycophenolate Mofetil for Prevention of Graft-Versus-Host Disease after Myeloablative Related and Unrelated Donor Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2021, 138, 99-99.	0.6	0
25	Post-Transplant Inotuzumab Ozogamicin for Acute Lymphoblastic Leukemia. <i>Blood</i> , 2021, 138, 2899-2899.	0.6	1
26	Community Health Status and Long-Term Outcomes in 1-Year Survivors of Autologous and Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2021, 138, 422-422.	0.6	0
27	Updates in chronic graft-versus-host disease. <i>Hematology American Society of Hematology Education Program</i> , 2021, 2021, 648-654.	0.9	24
28	Therapeutic Dose Monitoring of Busulfan Is Associated with Reduced Risk of Relapse in Non-Hodgkin Lymphoma Patients Undergoing Autologous Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 262-271.	2.0	17
29	Comparative effectiveness of busulfan/cyclophosphamide versus busulfan/fludarabine myeloablative conditioning for allogeneic hematopoietic cell transplantation in acute myeloid leukemia and myelodysplastic syndrome. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2020, 13, 160-165.	0.6	8
30	Disability Related to Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 772-777.	2.0	16
31	Influence of major histocompatibility complex class I chain-related gene A polymorphisms on cytomegalovirus disease after allogeneic hematopoietic cell transplantation. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2020, 13, 32-39.	0.6	7
32	Quality-of-Life Trajectories in Adolescent and Young Adult versus Older Adult Allogeneic Hematopoietic Cell Transplantation Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1505-1510.	2.0	11
33	A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2139-2146.	2.0	14
34	Patient-reported outcomes in acute graft-versus-host disease: optimizing patient care and clinical trial endpoints. <i>Bone Marrow Transplantation</i> , 2020, 55, 1533-1539.	1.3	4
35	Interleukin-27 Enforces Regulatory T Cell Functions to Prevent Graft-versus-Host Disease. <i>Frontiers in Immunology</i> , 2020, 11, 181.	2.2	13
36	Bone Health Management After Hematopoietic Cell Transplantation: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1784-1802.	2.0	14

#	ARTICLE	IF	CITATIONS
37	Refined National Institutes of Health response algorithm for chronic graft-versus-host disease in joints and fascia. <i>Blood Advances</i> , 2020, 4, 40-46.	2.5	11
38	Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1459-1468.	2.0	35
39	Ixazomib for Treatment of Refractory Chronic Graft-versus-Host Disease: A Chronic GVHD Consortium Phase II Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1612-1619.	2.0	12
40	Non-Infectious Pulmonary Toxicity after Allogeneic Hematopoietic Cell Transplantation (HCT): A Center for International Blood and Marrow Transplant Research (CIBMTR) Study. <i>Blood</i> , 2020, 136, 7-8.	0.6	0
41	Resource Utilization and Factors Prolonging Hospitalization for Patients with Relapsed and Refractory Large B-Cell Lymphoma Receiving Tisagenlecleucel Versus Axicabtagene Ciloleucel. <i>Blood</i> , 2020, 136, 38-39.	0.6	2
42	Comparison of Outcomes and Quality-of-Life Measures Following Haploidentical Vs. Matched Related/Unrelated Donor Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2020, 136, 16-17.	0.6	0
43	Hematopoietic Progenitor Cell Mobilization and Collection for Autologous Hematopoietic Cell Transplantation in AL Amyloidosis: A Single Center Experience. <i>Blood</i> , 2020, 136, 26-27.	0.6	0
44	Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: From Recapitulation/Acquisition of Leukemogenic Hits to Immune Escape Due to Somatic Class I/ II HLA Mutations. <i>Blood</i> , 2020, 136, 21-21.	0.6	0
45	The Chronic Graft-versus-Host Disease Failure-Free Survival (cGVHD-FFS) Index. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2468-2473.	2.0	4
46	Psychosocial Assessment of Candidates for Transplant (PACT) as a tool for psychological and social evaluation of allogeneic hematopoietic cell transplantation recipients. <i>Bone Marrow Transplantation</i> , 2019, 54, 1443-1452.	1.3	21
47	Inferior Outcomes with Cyclosporine and Mycophenolate Mofetil after Myeloablative Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1744-1755.	2.0	10
48	Organ Changes Associated with Provider-Assessed Responses in Patients with Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1869-1874.	2.0	1
49	Breath analysis in gastrointestinal graft-versus-host disease after allogeneic hematopoietic cell transplantation. <i>Blood Advances</i> , 2019, 3, 2732-2737.	2.5	9
50	Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes. <i>Blood Advances</i> , 2019, 3, 4228-4237.	2.5	34
51	Mutation clonal burden and allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia and myelodysplastic syndromes. <i>Bone Marrow Transplantation</i> , 2019, 54, 1281-1286.	1.3	24
52	Effect of bone marrow CD34+ cells and T-cell subsets on clinical outcomes after myeloablative allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2019, 54, 775-781.	1.3	14
53	Employment, Insurance, and Financial Experiences of Patients with Chronic Graft-versus-Host Disease in North America. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 599-605.	2.0	20
54	Targeted Treatment and Survival Following Relapse after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia and MDS in the Contemporary Era. <i>Blood</i> , 2019, 134, 4567-4567.	0.6	3

#	ARTICLE	IF	CITATIONS
55	Long-Term Experience with Large Granular Lymphocytic Leukemia Evolving after Solid Organ and Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2019, 134, 1226-1226.	0.6	0
56	Prognostic Factors for Mortality among Day +100 Survivors after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1029-1034.	2.0	19
57	Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1. <i>Blood Cancer Journal</i> , 2018, 8, 4.	2.8	43
58	Prognostic impact of incomplete hematologic count recovery and minimal residual disease on outcome in adult acute lymphoblastic leukemia at the time of second complete response. <i>Leukemia and Lymphoma</i> , 2018, 59, 363-371.	0.6	4
59	Association of Socioeconomic Status with Chronic Graft-versus-Host Disease Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 393-399.	2.0	24
60	Prognostic value of pre-transplant PET/CT in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2018, 59, 1195-1201.	0.6	11
61	Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 726-733.	2.0	71
62	Efficacy of Standard Dose R-CHOP Alternating With R-HDAC Followed by Autologous Hematopoietic Cell Transplantation as Initial Therapy of Mantle Cell Lymphoma, a Single-Institution Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e95-e102.	0.2	6
63	Neutropenic fever during peripheral blood progenitor cell mobilization is associated with decreased CD34+ cell collection and increased apheresis collection days. <i>Journal of Clinical Apheresis</i> , 2018, 33, 303-309.	0.7	6
64	Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia. <i>Blood Advances</i> , 2018, 2, 2922-2936.	2.5	35
65	Current approaches to prevent and treat GVHD after allogeneic stem cell transplantation. <i>Hematology American Society of Hematology Education Program</i> , 2018, 2018, 228-235.	0.9	32
66	TBI: To Be (Irradiated) or Not To Be? That Remains the Question. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1535-1536.	2.0	1
67	Impact of Venous Thromboembolism during High Intensity Chemotherapy for Acute Leukemia Patients on Duration of Hospital Stay. <i>Blood</i> , 2018, 132, 4806-4806.	0.6	1
68	Association of MHC Class I Chain-Related Gene a (MICA) Polymorphisms with Allogeneic Hematopoietic Cell Transplantation Outcomes in Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 2075-2075.	0.6	0
69	Allogeneic Hematopoietic Cell Transplantation for Adult T Cell Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1117-1121.	2.0	32
70	The association of histologic grade with acute graft-versus-host disease response and outcomes. <i>American Journal of Hematology</i> , 2017, 92, 683-688.	2.0	9
71	Impact of allogeneic hematopoietic cell transplant in patients with myeloid neoplasms carrying spliceosomal mutations. <i>American Journal of Hematology</i> , 2016, 91, 406-409.	2.0	20
72	Metabolic Syndrome and Cardiovascular Disease after Hematopoietic Cell Transplantation: Screening and Preventive Practice Recommendations from the CIBMTR and EBMT. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1493-1503.	2.0	55

#	ARTICLE	IF	CITATIONS
73	Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. <i>Journal of Clinical Oncology</i> , 2016, 34, 1864-1871.	0.8	61
74	Daily Weight-Based Busulfan with Cyclophosphamide and Etoposide Produces Comparable Outcomes to Four-Timesâ€œDaily Busulfan Dosing for Lymphoma Patients Undergoing Autologous Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1588-1595.	2.0	9
75	Using Molecular Data in Allogeneic Hematopoietic Cell Transplantation Outcomes for Acute Myeloid Leukemia: Underestimating True Tumor Diversity?. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1911-1912.	2.0	0
76	Association of Socioeconomic Status with Outcomes of Autologous Hematopoietic Cell Transplantation for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1141-1144.	2.0	9
77	Molecular and Immunophenotypic Characteristics of Adult Acute Leukemias of Ambiguous Lineage. <i>Blood</i> , 2016, 128, 1659-1659.	0.6	2
78	Prognostic Factors for Late Mortality Among Day 100 Survivors after Allogeneic Hematopoietic Cell Transplantation (HCT). <i>Blood</i> , 2016, 128, 4666-4666.	0.6	0
79	Non-t(6;9) and Non-Inv(3) Balanced Chromosomal Rearrangements Are Associated With Poor Survival Outcomes in Myelodysplastic Syndromes. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 489-495.	0.2	4
80	Comparison of Outcomes of Allogeneic Transplantation for Chronic Myeloid Leukemia with Cyclophosphamide in Combination with Intravenous Busulfan, Oral Busulfan, or Total Body Irradiation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 552-558.	2.0	12
81	Cyclosporine in combination with mycophenolate mofetil versus methotrexate for graft versus host disease prevention in myeloablative HLA-identical sibling donor allogeneic hematopoietic cell transplantation. <i>American Journal of Hematology</i> , 2015, 90, 144-148.	2.0	27
82	Long-term survival after high-dose chemotherapy with autologous hematopoietic cell transplantation in metastatic breast cancer. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2015, 8, 115-124.	0.6	3
83	Prognostic Impact of Molecular Mutations in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) on Allogeneic Hematopoietic Cell Transplant (HCT) Outcomes: Adverse Impact of TET2 Mutations. <i>Blood</i> , 2015, 126, 740-740.	0.6	3
84	Association of Socioeconomic Status (SES) with Outcomes of Autologous Hematopoietic Cell Transplantation (ASCT) for Lymphoma. <i>Blood</i> , 2015, 126, 4494-4494.	0.6	0
85	Maximizing the Benefits of Mycophenolate Mofetil as Graft-versus-Host Disease Prophylaxis. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1869-1870.	2.0	1
86	Sustained disease-free survival achieved with withdrawal of immunosuppression after rapid relapse of myelodysplastic syndrome following myeloablative allogeneic hematopoietic transplantation: a case report. <i>Journal of Medical Case Reports</i> , 2013, 7, 18.	0.4	1
87	Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI. <i>Blood</i> , 2013, 122, 3863-3870.	0.6	153
88	Concise Review: The Role of Hematopoietic Stem Cell Transplantation in the Treatment of Acute Myeloid Leukemia. <i>Stem Cells</i> , 2012, 30, 1581-1586.	1.4	45
89	Impact of Mutations in the Spliceosome Machinery and Ring Sideroblasts in Patients with Myeloid Malignancies Who Received Conventional Chemotherapy or Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2012, 120, 1973-1973.	0.6	2
90	Omission of Methotrexate Doses Due to Toxicity Does Not Influence the Incidence of Gvhd, Relapse, or Survival. <i>Blood</i> , 2012, 120, 4189-4189.	0.6	1